Artiva Biotherapeutics, Inc. Payments to Acquire Investments
Artiva Biotherapeutics, Inc. (ARTV) reported Payments to Acquire Investments of $6.44 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireInvestments · last filed 2026-08-06
- Artiva Biotherapeutics, Inc. payments to acquire investments for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- Artiva Biotherapeutics, Inc. payments to acquire investments for the quarter ending 2026-03-31 was $6.44M, a 65.21% decline year-over-year.
- Artiva Biotherapeutics, Inc. payments to acquire investments for the quarter ending 2025-12-31 was $7.54M, a 49.24% decline year-over-year.
- Artiva Biotherapeutics, Inc. payments to acquire investments for the quarter ending 2025-09-30 was $12.74M, a 91.08% decline year-over-year.
- Artiva Biotherapeutics, Inc. payments to acquire investments for fiscal 2025 was $44.88M, a 74.53% decline from fiscal 2024.
- Artiva Biotherapeutics, Inc. payments to acquire investments for fiscal 2024 was $176.17M.
| Period end | Payments to Acquire Investments 3 month | Payments to Acquire Investments 6 month | Payments to Acquire Investments 9 month | Payments to Acquire Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $6.44M 10-Q · filed 2026-08-06 | $13.98M derived: sum of 3 quarters · filed 2026-08-06 | $26.73M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $6.44M 10-Q · filed 2026-05-08 | $13.98M derived: sum of 2 quarters · filed 2026-05-08 | $26.73M derived: sum of 3 quarters · filed 2026-05-08 | $32.80M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $7.54M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $20.28M derived: sum of 2 quarters · filed 2026-03-10 | $26.36M derived: sum of 3 quarters · filed 2026-08-06 | $44.88M 10-K · filed 2026-03-10 |
| 2025-09-30 | $12.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $18.82M derived: sum of 2 quarters · filed 2026-08-06 | $37.34M 10-Q · filed 2025-11-12 | $52.19M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $6.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $24.59M 10-Q · filed 2026-08-06 | $39.44M derived: sum of 3 quarters · filed 2026-08-06 | $182.38M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $18.52M 10-Q · filed 2026-05-08 | $33.37M derived: sum of 2 quarters · filed 2026-05-08 | $176.30M derived: sum of 3 quarters · filed 2026-05-08 | $188.49M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $14.85M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $157.78M derived: sum of 2 quarters · filed 2026-03-10 | $169.97M derived: sum of 3 quarters · filed 2026-03-10 | $176.17M 10-K · filed 2026-03-10 |
| 2024-09-30 | $142.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $155.12M derived: sum of 2 quarters · filed 2025-11-12 | $161.32M 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $12.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $18.39M 10-Q · filed 2025-08-06 | ||
| 2024-03-31 | $6.20M 10-Q · filed 2025-05-08 | |||
| 2023-09-30 | $34.69M 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |